Neurocrine's Ingrezza continues tardive dyskinesia dominance
Neurocrine Biosciences (NBIX) continues to impress with Ingrezza's tardive dyskinesia launch, with the drug securing nearly $200M in revenue for Q3 '19:
Figure 2: Ingrezza marches towards blockbuster status (> $250M/quarter in revenue) (Source: Neurocrine corporate slides)
Neurocrine's only competition for this blockbuster indication (tardive dyskinesia) is Teva's (TEVA) Austedo, which sees itself underperforming relative to Ingrezza:
Figure 3: Austedo, relative to Ingrezza, has underwhelming revenue numbers, but because of the market opportunity, is seeing decent growth (Source: TEVA)
Ingrezza's impressive growth has